Has Jan Widerman received payments from drug or device companies?

Yes. Drug and device makers reported $2,010 in general payments to Jan Widerman across 124 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jan Widerman did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jan Widerman come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jan Widerman

Pediatrics · Philadelphia, PANPI 1023197977

Payments from drug & device makers

$2,010in general payments, 2019–2025

Across 124 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Alkermes, Inc.$591
Braeburn Inc.$337
Takeda Pharmaceuticals U.S.A., Inc.$336
Corium, LLC$137
Orexo US, Inc.$134
Supernus Pharmaceuticals, Inc.$133
plus $342 from 8 others

$27,581in research payments, 2019–2025

Across 13 payments — averaging $2121.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Orexo US, Inc.$28K

What the payments were for

Food & beverage$2,005100%
Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Alkermes, Inc.	26	$591
Braeburn Inc.	28	$337
Takeda Pharmaceuticals U.S.A., Inc.	23	$336
Corium, LLC	9	$137
Orexo US, Inc.	13	$134
Supernus Pharmaceuticals, Inc.	6	$133
Ironshore Pharmaceuticals Inc.	5	$84
GSK	3	$63
Arbor Pharmaceuticals, Inc.	3	$51
Merck	3	$45
Tris Pharma Inc	2	$41
Pfizer	1	$23
Ironwood Pharmaceuticals, Inc	1	$19
Pear Therapeutics (US), Inc.	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VIVITROL$124

How this compares

$2,010 in reported general payments places this provider in the 90th percentile of 1,849 pediatrics providers in Pennsylvania.

See all pediatrics providers in Pennsylvania →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl	693	$153,474
ArexvyRsvpref3 Antigen/As01e/Pf	27	$8,156
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine	129	$6,020
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	149	$3,918
ShingrixVaricella-Zoster Ge/As01b/Pf	16	$3,431
Buprenorphine Hcl	24	$2,657
Gabapentin	117	$1,640
Naproxen	56	$597
Pregabalin	21	$511
Oxycodone Hcl	25	$458
Sertraline Hcl	22	$335
Bupropion XlBupropion Hcl	18	$301
Diazepam	33	$274
Cyclobenzaprine Hcl	36	$256
Clonazepam	20	$247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
GSKArexvy, Shingrix	$63	$11,58743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,849 pediatrics providers in Pennsylvania.

Other pediatrics in Philadelphia

Theodore LaetschPhiladelphia$4.3M
Jennifer CohenPhiladelphia$214K
Matthew EliasPhiladelphia$110K
Levon UtidjianPhiladelphia$94K
Kristopher BossePhiladelphia$90K
Binita Kamath PatelPhiladelphia$80K
Beth MoughanPhiladelphia$64K
Kandace GollompPhiladelphia$59K
Roberta LaguerrePhiladelphia$44K
Pamela McDonnellPhiladelphia$42K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →